

FOR IMMEDIATE RELEASE

12th September 2019

Glycostem welcomes US based Dr Rizwan Romee to its advisor board

12th September 2019, Oss, The Netherlands — Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced to have welcomed Rizwan Romee, MD, associate professor at Harvard Medical School/Dana Faber Cancer Institute as member of Glycostem's advisory Board.

Dr Rizwan Romee said "I have been aware of Glycostem's advances in the field of NK-cells and we share the passion and belief that NK-cells has a natural place in the treatment of cancers. I am looking forward to be working with the successful team at Glycostem to advance NK-cells in the field of cancer in the USA and beyond."

Troels Jordansen, CEO said "We are delighted to welcome Dr Rizwan Romee to our Advisory Board where he will join a distinguished group of advisors. Dr Romee's keen interest and belief in NK-cells will be very useful when Glycostem turns its attention to the US market for commercialisation and co-development partners for CAR-NK products. This also goes for our discussions with the FDA on our lead product oNKord® (non-manipulated NK-cells)."

[To be continued on next page]



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com - www.Glycostem.com

Rizwan Romee, MD works as associate professor of medicine at Harvard Medical School/Dana Farber Cancer Institute since March '18. Before this Dr Romee received his MD from Govt. Medical College Srinagar, India in 2003. He completed his postgraduate training and haematology/oncology fellowship at University of Minnesota in 2011. He did his postdoctoral training in Dr Jeffry S. Miller's laboratory at University of Minnesota followed by advanced BMT fellowship and post-doctoral training in Dr Todd Fehniger's laboratory at Washington University School of Medicine in 2012. At Dana Farber Cancer Institute (DFCI) and Harvard Medical School, Dr Romee's goal is to expand the use of NK-cell based studies in patients with advanced hematologic malignancies and also to test them in combination with other novel agents to potentially further enhance their anti-tumour activity.

- end -

About Glycostem

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem's products are a safer alternative to CAR-T-cells as there are no Graft versus Host Disease. Glycostem's lead product, oNKord[®], is manufactured from allogeneic raw material and is available off-the shelf.

oNKord[®] is produced in a closed system in Glycostem's state-of-the-art and GMP (Good Manufacturing Process) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes *ex vivo* generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord[®] successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). Results indicate that oNKord[®] may be safely infused in patients with AML patients.



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

Glycostem is furthermore developing a range of CAR-NK products in-house and in cooperation with global partners including MolMed SPA (BIT:MLM).

Thanks to its eight patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market.



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com